ISRIB treatment did not reduce the viability of any of the three PDOs (Fig. 1F,G), suggesting that the canonical targeting of the eIF2B/p-eIF2α axis via ISRIB might not be a reasonable therapeutic approach in the treatment of CRC. This evidence concerns the gene EIF2B5 and colorectal carcinoma.